Form 4: Rocket Pharma CMO Boosts Stake with Equity Grants

Rocket Pharmaceuticals' Chief Medical Officer, Syed Ali-aamir Rizvi, increased his beneficial ownership through new grants of Restricted Stock Units and stock options.

Summary

• Syed Ali-aamir Rizvi, Chief Medical Officer of Rocket Pharmaceuticals, Inc. (RCKT), acquired 61,963 shares of common stock in the form of Restricted Stock Units (RSUs) on February 11, 2026, at a price of $0 per share.
• These RSUs will vest one-third on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the subsequent two years.
• Following this transaction, Rizvi beneficially owns 407,874 shares of common stock directly.
• Additionally, Rizvi acquired stock options to purchase 93,037 shares of common stock on February 11, 2026, with an exercise price of $3.24 per share.
• These stock options will become exercisable one-third on February 11, 2027, with the remaining options vesting in equal quarterly installments over the following two years, subject to continued employment.
• The stock options have an expiration date of February 11, 2036.
• Following this transaction, Rizvi beneficially owns 93,037 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as increased insider ownership through equity grants generally signals management's confidence and commitment to the company's long-term success.

Positives

• The grant of Restricted Stock Units and stock options to the Chief Medical Officer increases his direct beneficial ownership, aligning his interests with those of shareholders.
• The vesting schedule over several years encourages long-term commitment and performance from a key executive.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that significant equity grants to key executives like a Chief Medical Officer are a common practice in the biotechnology and pharmaceutical industry. Such grants are typically designed to incentivize long-term performance, retain talent, and align executive interests with shareholder value creation, especially given the long development cycles inherent in drug discovery.

Related Party Transactions

• The grants of 61,963 Restricted Stock Units and options to purchase 93,037 shares of common stock to Syed Ali-aamir Rizvi, the Chief Medical Officer, constitute related party transactions as they represent compensation from the issuer to an executive officer.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value due to greater equity ownership and long-term vesting incentives.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to executive incentives.

Next Steps

• One-third of the granted Restricted Stock Units and stock options will vest on February 11, 2027.
• The remaining RSUs and stock options will vest in equal quarterly installments over the subsequent two years, subject to continued employment.

Key Dates

Keywords

RCKT, Rocket Pharmaceuticals, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Beneficial Ownership, Chief Medical Officer